International Research Journal of Medical Sciences _____ISSN 2320 – 7353
Vol. **13(1),** 8-12, February **(2025)** *Int. Res. J. Medical Sci.*

Innovative approaches in targeting Cancer Metabolism with small molecules

Ansar Bilyaminu Adam[1], Musa Yahaya Abubakar[1] and Audu H.[2]
[1]Department of Chemical Sciences, Federal University Wukari, Taraba State, Nigeria
[2]Department of Biological science, Federal College of Education Okene, Kogi State, Nigeria
yahayaabubakarmusa@gmail.com

Available online at: www.isca.in
Received 22nd November 2024, revised 28th December 2024, accepted 30th January 2025

Abstract

The reprogramming of metabolic pathways is fundamental to cancer cell proliferation and survival, making cancer metabolism a pivotal field for therapeutic advancements. This study investigates the creation and utilization of small molecule inhibitors aimed at critical metabolic routes, such as glycolysis, the tricarboxylic acid (TCA) cycle, and lipid metabolism. By interfering with these pathways, small molecules present a promising approach to hinder tumor growth and enhance the efficacy of current cancer treatments. The research highlights novel strategies in crafting selective and potent inhibitors, tackling challenges like specificity and resistance. Furthermore, it delves into the potential of integrating these small molecules into personalized cancer therapies. The outcomes underscore the promise of targeting metabolic weaknesses as a transformative strategy in cancer treatment.

Keywords: Cancer Metabolism, Small Molecules, Glycolysis Inhibition, Lipid Metabolism, Enzyme Inhibitors.

Introduction

Cancer cells undergo significant metabolic adaptations to fulfill the increased energy and biosynthetic needs associated with their rapid growth. These metabolic shifts enable them to survive in hostile tumor microenvironments, which may lack sufficient oxygen or nutrients, thereby opening avenues for therapeutic strategies. Unlike normal cells, which predominantly utilize oxidative phosphorylation for ATP generation, many cancer cells prefer glycolysis, even when oxygen is available. This alternative pathway provides not only energy but also essential building blocks for cellular growth[1].

Small molecule inhibitors that target the unique metabolic dependencies of cancer cells are emerging as a promising therapeutic strategy. For instance, inhibitors of glycolysis aim to block the primary energy source for cancer cells. Preclinical studies have demonstrated that inhibiting enzymes such as hexokinase and lactate dehydrogenase can significantly reduce tumor growth[2]. By disrupting glycolytic flux, these inhibitors not only diminish ATP production but also hinder the synthesis of vital biomolecules required for tumor progression. In addition to glycolysis, lipid metabolism plays a crucial role in cancer cell survival, with many tumor cells showing enhanced fatty acid synthesis to support membrane formation and signaling. Targeting fatty acid synthase (FASN) with small molecule inhibitors has demonstrated efficacy in preclinical studies, effectively interfering with lipid biosynthesis and suppressing tumor growth[3]. This approach takes advantage of the tumor's reliance on de novo lipid synthesis, a process less active in normal tissues.

Moreover, the role of amino acid metabolism in cancer therapy is gaining increasing attention. Glutamine, a key nutrient for many tumors, is critical for both energy production and the synthesis of macromolecules. Inhibiting glutaminase, the enzyme that converts glutamine into glutamate, has shown promise in preclinical models, disrupting the glutamine-driven metabolic pathways that are essential for cancer cell survival[4].

Cancer metabolism and its therapeutic implications

Cancer cells undergo significant metabolic reprogramming, adjusting key metabolic pathways such as glycolysis, oxidative phosphorylation (OXPHOS), fatty acid metabolism, and amino acid metabolism to meet their elevated energy, biosynthetic, and survival requirements. A hallmark feature of cancer metabolism is its remarkable flexibility, which enables cells to shift between these pathways depending on nutrient availability and oxygen levels. This flexibility allows cancer cells to thrive in diverse and often harsh tumor microenvironments[5].

A defining characteristic of cancer metabolism is the shift toward aerobic glycolysis, known as the Warburg effect. In this process, cancer cells preferentially rely on glycolysis for energy production, even when oxygen levels are sufficient, to satisfy their increased energy demands and support biosynthesis. This metabolic adaptation not only produces ATP but also generates key intermediates needed for the synthesis of macromolecules that drive rapid cell division[6].

Alongside glycolysis, many cancer cells reprogram their oxidative phosphorylation machinery, enhancing their ability to adapt to changing environmental conditions, such as nutrient

deprivation or low oxygen levels[7]. This ability to use both glycolysis and OXPHOS enables cancer cells to sustain energy production regardless of fluctuations in the microenvironment.

Fatty acid metabolism is another essential pathway in cancer cell adaptation. Many cancer cells increase fatty acid synthesis to support membrane production, energy storage, and signaling processes. Additionally, they may enhance fatty acid oxidation to provide energy during periods of metabolic stress or nutrient scarcity[8].

Amino acid metabolism, particularly the process of glutaminolysis, is also crucial for cancer cell survival. Glutamine serves as a key substrate for the tricarboxylic acid (TCA) cycle, supplying both carbon and nitrogen for nucleotide and amino acid synthesis. Beyond its role in biosynthesis, glutamine also helps maintain redox balance, making it an attractive target for therapeutic intervention[9].

Glycolysis in Cancer Metabolism

One of the key metabolic adaptations in cancer cells is the Warburg effect, a phenomenon where tumor cells preferentially rely on glycolysis for ATP production, even in the presence of sufficient oxygen. This deviates from the classical view that oxidative phosphorylation (OXPHOS) is the primary energy source under aerobic conditions. Instead, cancer cells shift their metabolic focus to glycolysis, which, despite being less efficient in terms of ATP yield, provides several advantages for rapidly proliferating cells[6].

This metabolic reprogramming not only supports increased energy production but also enables cancer cells to thrive in environments where oxygen and nutrients are scarce, conditions commonly encountered in solid tumors. The ability to switch between OXPHOS and glycolysis allows cancer cells to maintain growth and survival in hostile microenvironments that would otherwise inhibit the proliferation of normal cells[8].

$$C_6H_{12}O_6 + 2\ NAD^+ + 2\ ADP + 2\ Pi \longrightarrow 2C_3H_4O_3\ (\text{pyruvate})$$

Cancer cells preferentially use glycolysis, even though it generates less ATP compared to oxidative phosphorylation, due to its faster rate of operation and its ability to provide essential biosynthetic intermediates. For instance, the glycolytic intermediate dihydroxyacetone phosphate (DHAP) is directed toward lipid biosynthesis, while glucose-6-phosphate (G6P) feeds into the pentose phosphate pathway, yielding ribose-5-phosphate for the synthesis of nucleotides required for cell proliferation. Lactate production (end product of glycolysis under the Warburg effect).

$$\text{Pyruvate} + NADH + H^+ \longrightarrow \text{Lactate} + NAD^+$$

Lactate, produced through glycolysis, is exported from cancer cells into the surrounding tumor microenvironment. This export contributes to the acidification of the extracellular space, which can promote tumor invasion and hinder immune responses. The upregulation of this entire glycolytic pathway in cancer cells is often driven by the activation of oncogenes such as **MYC** and **RAS**, as well as the inactivation of tumor suppressors like **p53.**

Oxidative Phosphorylation

Although many cancer cells predominantly rely on glycolysis, they still maintain functional oxidative phosphorylation (OXPHOS) in their mitochondria. In this process, electrons are passed through theelectron transport chain (ETC), culminating in the reduction of oxygen to water. This electron transfer drives the phosphorylation of ADP to ATP, providing an additional source of cellular energy

Overall reaction of oxidative phosphorylation

$$C_6H_{12}O_6 + 6O_2 \longrightarrow 6CO_2 + 6H_2O + 36ATP$$

Oxidative phosphorylation (OXPHOS) is a far more efficient process than glycolysis, yielding significantly more ATP per glucose molecule. In certain cancers, particularly those with cancer stem cells or in conditions where glucose availability is limited, OXPHOS remains a critical energy source. This ability to switch between glycolysis and OXPHOS highlights the metabolic plasticity of cancer cells, allowing them to adapt and survive despite fluctuating levels of oxygen and nutrients.

Lipid Catabolism and Energy Production

Fatty acid metabolism plays a crucial role in cancer progression by providing essential lipids for membrane formation and serving as an alternative energy source through fatty acid oxidation (FAO). To meet the increased lipid biosynthesis demands necessary for rapid proliferation, cancer cells often enhance fatty acid synthesis (FAS). Dysregulated lipid metabolism not only promotes tumor growth but also contributes to resistance against treatments targeting other metabolic pathways [3,10].

Fatty acid synthesis reaction (simplified)

$$\text{Acetyl-CoA} + 7\text{Malonyl CoA} + 14NADPH \rightarrow \text{Palmitate } (C_{16}H_{32}O_2) + 7CO_2 + 14NADP^+$$

The enzyme fatty acid synthase (FASN) catalyzes this reaction, producing palmitate, a 16-carbon saturated fatty acid that serves as the precursor for more complex lipids. Over expression of FASN is common in many aggressive cancers and is associated with poor prognosis.

In addition to synthesis, cancer cells can also rely on fatty acid oxidation to generate ATP, particularly under nutrient-scarce conditions. In FAO, fatty acids are broken down in the mitochondria to acetyl-CoA, which enters the TCA cycle to produce ATP.

Amino Acid Metabolism

Amino acids are integral to cancer metabolism, extending beyond their role as protein building blocks. Among them, glutamine is particularly crucial for cancer cells, acting as a key source of both carbon and nitrogen. Through glutaminolysis, glutamine is metabolized into glutamate, which subsequently feeds into the TCA cycle, supporting energy generation and biosynthetic processes.

Glutaminolysis (initial step)
$Glutamine(C_5H_{10}N_2O_3) + H_2O \longrightarrow Glutamate(C_5H_9NO_4) + NH_3$

Glutamate is subsequently transformed into α-ketoglutarate, a key intermediate of the TCA cycle that supports anabolic pathways, including nucleotide and lipid biosynthesis.

α-Ketoglutarate Formation from Glutamate
$Glutamate + NAD^+ \longrightarrow \alpha-Ketoglutarate + NADH + NH_3$

Beyond glutamine, cancer cells increase the uptake of other amino acids, including serine, which plays a critical role in nucleotide synthesis and one-carbon metabolism. Certain cancers, particularly leukemias, exhibit a strong dependency on asparagine for survival. This reliance has driven the development of asparaginase, an enzyme-based therapy designed to deplete asparagine and hinder cancer cell growth.

Metabolic Flexibility and Adaptability in Tumors

A hallmark of cancer metabolism is its metabolic flexibility**,** allowing cancer cells to adapt to the changing tumor microenvironment. This flexibility is crucial for tumor survival in conditions of fluctuating oxygen and nutrient levels, such as hypoxic or nutrient-deprived regions within a tumor. Under hypoxic conditions, cancer cells up regulate glycolysis and reduce their reliance on oxidative phosphorylation. Conversely, in regions with sufficient oxygen but limited glucose, they may switch to fatty acid oxidation or rely on amino acid metabolism (e.g., glutaminolysis) to meet their energy and biosynthetic needs. This adaptability is a major reason why tumors can be resistant to therapies targeting single metabolic pathways, as they can activate alternative routes to survive.

Small Molecule Inhibitors in Cancer Metabolism: Targeting cancer metabolism with small molecule inhibitors has gained significant interest as a therapeutic approach due to the metabolic reprogramming that distinguishes cancer cells from normal cells. By disrupting key metabolic pathways that cancer cells rely on for growth and survival, small molecule inhibitors offer a potential strategy to selectively kill cancer cells. This section will provide an overview of various small molecule targets in cancer metabolism, focusing on glycolysis, mitochondrial function, and fatty acid synthesis, along with preclinical and clinical evidence of their efficacy.

Glycolytic Enzyme Inhibitors: The glycolytic pathway is upregulated in many cancers to support their rapid growth, making it an attractive target for inhibition.

Fatty Acid Synthesis Inhibitors

Many cancer cells rely on de novo fatty acid synthesis for membrane production, energy storage, and signaling molecules, making this pathway another therapeutic target.

Fatty Acid Synthase (FASN) Inhibitors: Fatty acid synthase (FASN) catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA, supplying essential precursors for membrane lipid formation and signaling molecule production.

$Acetyl\text{-}CoA + 7Malonyl\ CoA + 14NADPH \rightarrow Palmitate\ (C_{16}H_{32}O_2) + 7CO_2 + 14NADP^+$

Inhibitors like orlistat and C75 target FASN, leading to the accumulation of toxic lipid intermediates and reduced cell growth. Preclinical studies have shown that FASN inhibitors can reduce tumor growth in various cancer models, and these compounds are being evaluated for clinical development.

Biochemical Pathways Affected by Small Molecule Inhibitors: The role of small molecule inhibitors in cancer metabolism primarily involves

Starvation of energy: Inhibiting key enzymes like HK2 or LDH-A disrupts ATP production, making it harder for cancer cells to sustain their rapid growth and division.

Disruption of biosynthesis: Inhibiting enzymes responsible for fatty acid or amino acid metabolism disrupts the synthesis of essential building blocks needed for cell proliferation.

Induction of metabolic stress: Compounds like metformin increase AMPK activity, promoting catabolic processes that inhibit cancer growth while sensitizing cells to metabolic stress.

Preclinical Studies and Clinical Trials

Preclinical studies have highlighted the potential of small molecule inhibitors in cancer treatment. For example, 2-deoxy-D-glucose (2-DG) has shown promise in slowing down tumor growth in cancers that rely on glycolysis, though its high-dose toxicity is a major concern[11]. In a similar vein, FX11, which targets lactate dehydrogenase (LDH), has been effective in reducing tumor size in lymphoma and pancreatic cancer models[12].

Metformin, a drug often used to manage type 2 diabetes, is gaining attention in cancer research. When combined with chemotherapy or targeted treatments, it has shown potential in preclinical studies, and clinical trials are currently underway for cancers like breast and colorectal[13]. Then there's orlistat, an

inhibitor of fatty acid synthase (FASN), which has also demonstrated the ability to slow tumor growth in prostate and breast cancer models. Several of these inhibitors are already in early-phase clinical trials[14].

Challenges and Limitations in Targeting Cancer Metabolism

Targeting cancer metabolism with small molecule inhibitors is definitely a promising approach, but there are a few hurdles that need to be tackled before it can reach its full potential. For one, drug resistance is a big issue, along with the fact that tumors are incredibly diverse and can change over time. On top of that, there are concerns about off-target effects and how flexible cancer cells can be when it comes to their metabolism.

Drug Resistance Mechanisms

Cancer cells exhibit remarkable adaptability, often developing resistance to therapies targeting their metabolic pathways. Key mechanisms contributing to this resistance include: Activation of Alternative Pathways: Cancer cells may upregulate compensatory pathways when facing metabolic inhibition. For example, blocking glycolysis may prompt an increased reliance on mitochondrial oxidative phosphorylation (OXPHOS) or other metabolic routes to sustain energy production and survival[15]. Genetic Adaptations: Mutations in metabolic enzyme genes can undermine the effectiveness of small molecule inhibitors. Alterations in target enzymes often prevent effective drug binding, reducing therapeutic efficacy[16].

Upregulation of Survival Pathways: Cancer cells frequently activate survival signaling pathways, such as the PI3K/AKT pathway, in response to metabolic stress. These pathways enhance glucose uptake and enable cancer cells to overcome metabolic blockade, facilitating continued growth and survival[13].

Tumor Heterogeneity: Tumor heterogeneity significantly complicates the targeting of cancer metabolism. Cancer is not a uniform disease; even within a single tumor, cancer cells can exhibit diverse metabolic profiles. This heterogeneity presents challenges such as: i. Metabolic Variability among Subpopulations: Different subsets of cancer cells may rely on distinct metabolic pathways. For example, while some cells depend primarily on glycolysis, others may utilize oxidative phosphorylation or fatty acid metabolism for energy production[15]. ii. Resistance of Cancer Stem Cells: Cancer stem cells within tumors often display unique metabolic properties, rendering them more resistant to metabolic inhibitors. These cells can shift their metabolic reliance depending on environmental conditions, making it difficult to target them with a single inhibitor[12]. iii. Tumor Microenvironment Complexity: The tumor microenvironment influences metabolic activity, with hypoxic regions favoring glycolysis and oxygenated regions relying more on mitochondrial respiration. This complexity complicates efforts to target all metabolic dependencies within a tumor effectively[11].

Conclusion

While small molecule inhibitors targeting cancer metabolism hold great potential, significant challenges must be addressed to fully realize their therapeutic benefits. Drug resistance, tumor heterogeneity, off-target effects, and the adaptability of cancer cells make it difficult to achieve durable responses with current metabolic therapies. To overcome these limitations, future approaches may involve combination therapies that target multiple metabolic pathways simultaneously, personalized treatments based on the metabolic profile of individual tumors, and strategies to reduce off-target toxicity while enhancing selectivity for cancer cells.

References

1. Warburg, O. (1956). On the origin of cancer cells. *Science*, 123(3191), 309-314.

2. Zhao, Y., Zhou, Z., Li, X., & Wang, L. (2021). Inhibiting glycolysis as a therapeutic strategy in cancer. *Cancer Research*, 81(10), 2419-2429.

3. Menendez, J. A., & Lupu, R. (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nature Reviews Cancer*, 7(10), 801-814.

4. Altman, B. J., Stine, Z. E., & Dang, C. V. (2016). Glutamine metabolism in cancer. *Cell Metabolism*, 24(1), 1-11.

5. Pavlova, N. N., & Thompson, C. B. (2016). The emerging hallmarks of cancer metabolism. *Cell Metabolism*, 23(1), 27-47.

6. Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science*, 324(5930), 1029-1033.

7. Martinez-Outschoorn, U. E., Trimmer, C. K., &Lisanti, M. P. (2017). Mitochondrial oxidative phosphorylation and cancer cell metabolism. *Journal of Clinical Investigation*, 127(3), 1229-1238.

8. Carracedo, A., Cejas, P., &Laderoute, K. (2013). Cancer metabolism: Fatty acid oxidation in the metabolic transformation of cancer cells. *Nature Reviews Cancer*, 13(4), 227-235.

9. DeBerardinis, R. J., & Cheng, T. (2010). Q & A: The multifaceted role of glutamine in cancer. *Nature Reviews Cancer*, 10(9), 537-547.

10. Currie, E., Schulze, A., & van der Heiden, M. G. (2013). Cellular metabolism and the regulation of cancer. *Nature Reviews Cancer*, 13(1), 27-43.

11. Pelicano, H., Carney, D., & Huang, P. (2006). Inhibition of glycolysis in cancer cells: Implications for therapy. *Drug Resistance Updates*, 9(6), 133-146.

12. Le, A., Gao, P., & Lee, J. (2010). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cell lymphomas. *Cell*, 142(3), 347-357.

13. Pollak, M. (2012). Metformin and other biguanides in oncology: Advances and mechanistic insights. *Nature Reviews Cancer*, 12(2), 1-14.

14. Menendez, J. A., Vellon, L., &Lupu, R. (2004). Fatty acid synthase: A key molecular target in cancer therapy. *Nature Reviews Cancer*, 4(5), 345-357.

15. Vander Heiden, M. G., & DeBerardinis, R. J. (2017). Understanding the intersections between metabolism and cancer biology. *Cell*, 168(4), 657-669.

16. Zhao, Y., Zhang, S., & Liu, T. (2020). Genetic alterations and resistance mechanisms in cancer metabolism. *Nature Reviews Cancer*, 20(4), 244-258.